Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participation in the AIO-TRK-0114 (MARBLE) study (EudraCT-No. 2014-001983-36)~2. Written informed consent~Exclusion Criteria:~1. Patients who do not meet the inclusion criterial of the AIO-TRK-0114 (MARBLE) study (EudraCT-No. 2014-001983-36)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Afatinib (Type: EXPERIMENTAL): Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
- Arm B: Pemetrexed (Type: EXPERIMENTAL): Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).